Literature DB >> 21849197

Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma?

Scott E Delacroix1, Brian F Chapin, Jaclyn J Chen, Graciela M Nogueras-Gonzalez, Pheroze Tamboli, Surena F Matin, Christopher G Wood.   

Abstract

PURPOSE: Patients with isolated regional nodal metastases from renal cell carcinoma are a distinct cohort for which resection of involved lymph nodes may be therapeutic. We assessed the outcomes of patients treated at our institution with pathological node positive renal cell carcinoma without concomitant metastatic disease (T(any)N+M0).
MATERIALS AND METHODS: A total of 2,521 patients with nonmetastatic renal cell carcinoma (T(any)N(any)M0) of any histological subtype treated with nephrectomy were identified between 1995 and 2009. Pathological regional node positive disease in the absence of clinically detectable metastases (T(any)N(1-2)M0) was present in 68 patients (2.7%) and these patients formed our study cohort. Patients were assessed for timing and location of recurrence, disease specific survival and overall survival. Multivariate Cox regression analysis was performed to define factors predictive of recurrence and overall survival.
RESULTS: Of the 68 patients with T(any)N(1-2)M0 renal cell carcinoma 22.1% were free of disease at a median followup of 43.5 months. In those patients experiencing recurrence, disease was detected within the first 4 months after surgery in 51% and was most commonly detected at multiple organ sites. The Kaplan-Meier estimated 5-year overall survival and disease specific survival was 37% and 39%, respectively. Predictors of a favorable outcome included an Eastern Cooperative Oncology Group performance status of 0, single node involvement, absence of sarcomatoid features and papillary histology.
CONCLUSIONS: Nephrectomy with lymph node dissection can provide a durable disease-free survival in a proportion of patients with regionally advanced renal cell carcinoma and limited lymph node metastases.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21849197     DOI: 10.1016/j.juro.2011.05.051

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  Analysis of lymph node dissection in patients with ≥7-cm renal tumors.

Authors:  Michael A Feuerstein; Matthew Kent; Wassim M Bazzi; Melanie Bernstein; Paul Russo
Journal:  World J Urol       Date:  2014-01-09       Impact factor: 4.226

Review 2.  The survival benefit of lymph node dissection at the time of removal of kidney, prostate and urothelial carcinomas: what is the evidence?

Authors:  Karim Bensalah; Morgan Roupret; Evanguelos Xylinas; Shahrokh Shariat
Journal:  World J Urol       Date:  2013-04-16       Impact factor: 4.226

Review 3.  The role of lymphadenectomy in the management of renal cell carcinoma.

Authors:  Glen W Barrisford; Boris Gershman; Michael L Blute
Journal:  World J Urol       Date:  2014-04-11       Impact factor: 4.226

4.  Trends and outcomes of lymphadenectomy for nonmetastatic renal cell carcinoma: A propensity score-weighted analysis of the National Cancer Database.

Authors:  Nicholas J Farber; Zorimar Rivera-Núñez; Sinae Kim; Brian Shinder; Kushan Radadia; Joshua Sterling; Parth K Modi; Sharad Goyal; Rahul Parikh; Tina M Mayer; Robert E Weiss; Isaac Y Kim; Sammy E Elsamra; Thomas L Jang; Eric A Singer
Journal:  Urol Oncol       Date:  2018-11-13       Impact factor: 3.498

5.  Role of RPLND and Metastasectomy in the Management of Oligometastatic Renal Cell Carcinoma.

Authors:  H Nagaraja; N Srivatsa; S Hemalatha; S Shweta; S K Raghunath
Journal:  Indian J Surg Oncol       Date:  2018-02-05

Review 6.  The role of lymph node dissection in renal cell carcinoma.

Authors:  Brian F Chapin; Scott E Delacroix; Christopher G Wood
Journal:  Int J Clin Oncol       Date:  2011-04-28       Impact factor: 3.402

7.  Extent of lymph node dissection improves overall survival in pT3N0 non-metastatic renal cell carcinoma patients treated with radical nephrectomy: a propensity score-based analysis.

Authors:  Yubin Wei; Maofeng Wang; Yili Jin; Changchun Zhou; Jia Lyu
Journal:  World J Urol       Date:  2019-05-07       Impact factor: 4.226

Review 8.  Beyond penile cancer, is there a role for sentinel node biopsy in urological malignancies?

Authors:  O R Brouwer; H G van der Poel; R F Bevers; E J van Gennep; S Horenblas
Journal:  Clin Transl Imaging       Date:  2016-07-04

Review 9.  Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.

Authors:  Brian M Shinder; Kevin Rhee; Douglas Farrell; Nicholas J Farber; Mark N Stein; Thomas L Jang; Eric A Singer
Journal:  Front Oncol       Date:  2017-05-31       Impact factor: 6.244

10.  Diagnostic and Prognostic Significance of Radiologic Node-positive Renal Cell Carcinoma in the Absence of Distant Metastases: A Retrospective Analysis of Patients Undergoing Nephrectomy and Lymph Node Dissection.

Authors:  Hye Won Lee; Hwang Gyun Jeon; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Han Yong Choi; Hyun Moo Lee
Journal:  J Korean Med Sci       Date:  2015-08-13       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.